Compare BridgeBio Pharma Inc (BBIO) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares Global Clean Energy ETF — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while iShares Global Clean Energy ETF trades at $19.2. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | ICLN | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $23.75 |
52-Week Low | $44.81 | $13.41 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
ICLN, the iShares Global Clean Energy ETF, trades at $18.625, down 3.25% on the day, with technical indicators showing a bearish trend. The ETF holds 105 global renewable energy companies and has delivered strong year-to-date performance, driven by increased energy demand and policy support. Recent news highlights comparisons with traditional energy and uranium ETFs, emphasizing ICLN's growth focus versus income alternatives.
Outlook remains mixed: clean energy benefits from structural trends like AI-driven power demand and global decarbonization goals, but risks include regulatory uncertainty and high volatility. The ETF's valuation and growth potential appeal to long-term investors, though near-term price action suggests caution amid bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
